Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on Jul 02, 2021 10:54am
109 Views
Post# 33481788

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Fitting

https://case.edu/cancer/sites/case.edu.cancer/files/2018-06/Dose-Limiting-Toxicity.pdf


SPCEO1 wrote: One of the science experts here should answer this but I will take a stab anyway:

1.) The MTD will be determined by stepping back one dosage level from the dosage that leads to two or more patients showing signs of toxicity. So, you can have one patient outof an eventual 6 who has a bad reaction to a dose and still make that your MTD. Clearly, TH is looking to be able to pump as much Docetaxel into a patient as possible as that should improve the efficacy but there is likely more to this equation than is readily apparent. The MTD might not be the dosage they end up using in the rest of the trials as they seek the best overall solution. For example, they could use the MTD early on to weaken the tumor and then fall back to lessor doses to extend the time the patient can be treated.

2.) I am not sure specifically, but I imagine toxicity is defined by any number of measures. The patient gets physically sick or their bloodwork shows any number of potential complications. I don't imagine that it is hard at all for TH to determine toxicity.

3.) In terms of this study, I imagine the toxicity has to show up in the first three week cycle to be initally relevant. But, if it does not show up in the first cycle, then the patients move onto to higher doses in a new cycle and toxicity can show up in those following cycles too. I don't think this drug lingers in the body much so I am not sure that time is as big a factor as dosage level. 

4.) Just guessing but if you stop taking Docetaxel as a normal cancer patient, you get better (at least in terms of side effects). I imagine that happens relatively quickly as it does not seem the drug accumulates in the body.

Those are my best guesses and they should be treated as guesses from a non-medically trained person giving it his best shot. Hopefully, someone who knows a lot more about this will make the appropriate corrections to what I have said. 
 

palinc2000 wrote: At what point do they determine that MTD has been reached,,,How is toxicity defined? Is there a time factor involved,,,?Can toxicity be reversed after a a few days .....?  




<< Previous
Bullboard Posts
Next >>